FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/10/095963 [Registered on: 13/10/2025] Trial Registered Prospectively
Last Modified On: 11/10/2025
Post Graduate Thesis  No 
Type of Trial  Observational 
Type of Study   Cohort Study 
Study Design  Other 
Public Title of Study   Comparison of 2 types of treatments, one given through blood route and other through lungs, for persistent seizures using blood tests 
Scientific Title of Study   Changes in neuronal cellular injury and neural inflammation during refractory status epilepticus (RSE) treatment with Isoflurane and Midazolam – a biomarker-based study 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  DR SONIA BANSAL 
Designation  Additional Professor 
Affiliation  NIMHANS 
Address  Department of Neuroanaesthesia and Neurocritical Care, 3rd floor, Faculty Block, Neurocentre, NIMHANS (near Bangalore Milk Dairy), Bengaluru

Bangalore
KARNATAKA
560029
India 
Phone  9008721921  
Fax    
Email  itz.sonia77@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  DR SONIA BANSAL 
Designation  Additional Professor 
Affiliation  NIMHANS 
Address  Department of Neuroanaesthesia and Neurocritical Care, 3rd floor, Faculty Block, Neurocentre, NIMHANS (near Bangalore Milk Dairy), Bengaluru

Bangalore
KARNATAKA
560029
India 
Phone  9008721921  
Fax    
Email  itz.sonia77@gmail.com  
 
Details of Contact Person
Public Query
 
Name  DR SONIA BANSAL 
Designation  Additional Professor 
Affiliation  NIMHANS 
Address  Department of Neuroanaesthesia and Neurocritical Care, 3rd floor, Faculty Block, Neurocentre, NIMHANS (near Bangalore Milk Dairy), Bengaluru

Bangalore
KARNATAKA
560029
India 
Phone  9008721921  
Fax    
Email  itz.sonia77@gmail.com  
 
Source of Monetary or Material Support  
Indian Society of Critical Care Medicine 
 
Primary Sponsor  
Name  Indian Society of Critical Care Medicine 
Address  Unit 13 and 14 First floor Hind Service Industries Premises Co operative Society Near Chaitya Bhoomi, Off Veer Savarkar Marg Dadar Mumbai400028 
Type of Sponsor  Other [Private Organisation] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
DR SONIA BANSAL  NIMHANS  Department of Neuroanaesthesia and Neurocritical Care, 3rd floor, Faculty block, Neurocentre
Bangalore
KARNATAKA 
09008721921

itz.sonia77@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institute Ethics Committee (BS and NS)  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: G409||Epilepsy, unspecified,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Nil  Nil 
Intervention  Nil  Nil 
Intervention  Nil  Nil 
Intervention  Nil  Nil 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  80.00 Year(s)
Gender  Both 
Details  Patients with refractory status epilepticus unresponsive to first line and two second line intravenous antiepileptics and requiring anesthetic medications to control seizures 
 
ExclusionCriteria 
Details  1.Known, suspected history of malignant hyperthermia
2.Patients with severe acute respiratory distress syndrome and arterial oxygen tension to inspired oxygen concentration ratio less than 100 requiring inverse ratio ventilation or prone ventilation
3.Patients with diagnosis of Mitochondrial disease
 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Compare the levels of serum NSE and IL-10 between patients receiving isoflurane and midazolam for treatment of RSE   At baseline before starting the drug and after stopping the drug (isoflurane or midazolam) 
 
Secondary Outcome  
Outcome  TimePoints 
In hospital mortality & Glasgow outcome scale extended   At discharge & 6 months after discharge 
 
Target Sample Size   Total Sample Size="40"
Sample Size from India="40" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   15/11/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="3"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

After admission to NCCU if patient is not intubated in the emergency department it will be done in the NCCU and patient will be ventilated

Vitals will be monitored every 15 min Patient will continue to receive the prescribed AEDs All patients will undergo complete hematology, biochemistry electrocardiography and neurological work-up in the form of computed tomography or Magnetic resonance Imaging scan cerebrospinal fluid examination if indicated toxicology screening and AED drug levels for patients on AEDs

If the seizures are not controlled with the initial benzodiazepine and two AEDs the patient will be diagnosed to have RSE and becomes eligible for the study Bispectral Index monitoring will be performed and wherever feasible cerebral oxygen saturation monitoring will also be done The patients will receive either midazolam or isoflurane for the treatment of RSE We plan to recruit alternate patient into midazolam and isoflurane group

In the midazolam group midazolam will be administered as a bolus of 0.05 mg per kg followed by initiation of infusion at 0.1mg per kg per hr. If the seizures recur more than three times in 15 min or the seizures are uncontrolled for 15 min then the dose will be escalated by 0.1 mg per kg per hr The dose at which seizures are controlled will be noted This escalation will continue if seizures are not terminated till a maximum dose of 0.4 mg per kg per h after which the RSE will be considered Super RSE and treatment failure of the study drug will be considered Thereafter thiopentone infusion will be initiated with a bolus of 3 mg per kg followed by a continuous infusion at a rate of 3 to 5 mg per kg per hr

In the isoflurane group isoflurane will be administered using anaesthesia machine and a dedicated vaporiser using a low flow technique and carbondioxide absorber circle system Isoflurane will be administrated at 0.6 MAC. If the seizures recur more than three times in 15 min, or the seizures are uncontrolled for 15 min then the dose will be escalated by 0.2 MAC This escalation will continue if seizures are not terminated till a maximum dose of 1.2 MAC The MAC at which seizures are controlled will be noted If seizures are not controlled even at 1.2 MAC RSE will be considered SRSE, and treatment failure of the study drug will be considered Thereafter thiopentone infusion will be initiated with a bolus of 3 mg per kg followed by a continuous infusion at a rate of 3 to 5 mg per kg per hr The dose at which seizures are controlled will be noted

If seizures are controlled with isoflurane or midazolam, the particular dose of the drug will be continued for 48 hours after which the dose will be reduced by 20 percent every 12 hours and eventually stopped.

At any stage of drug tapering if the seizures recur then tapering will be halted and the dose increased to the previous level and continued for another 24 h Tapering will be restarted if there is no seizure during this 24 h period

NSE and IL-10 levels

Blood samples for estimation of NSE and IL10 levels will be collected before starting the respective study drug and immediately after stopping the drug. A 2ml blood sample will be collected at each time point, the serum will be separated and stored

Estimation of NSE and IL10 levels will be done using ELISA technique using commercially available kits as per the manufacturer instructions

 
Close